China Biologic Products, a blood plasma company, received a $3.9 billion privatization offer from a management-led consortium of investors, topping a $3.6 billion offer from CITIC two months ago. The management-led offer is $118 per share, while CITIC offered $110. The consortium noted the offer represents a 30% premium to the previous closing stock price and a 40% premium to the close before the CITIC bid. Goldman Sachs will support the consortium’s fundraising efforts.
Source: China Biotoday
